The shared role of amyloid-β (Aβ) deposition in cerebral amyloid angiopathy (CAA) and Alzheimer disease (AD) is arguably the clearest instance of crosstalk between neurodegenerative and cerebrovascular processes. The pathogenic pathways of CAA and AD intersect at the levels of Aβ generation, its circulation within the interstitial fluid and perivascular drainage pathways and its brain clearance, but diverge in their mechanisms of brain injury and disease presentation. Here, we review the evidence for and the pathogenic implications of interactions between CAA and AD. Both pathologies seem to be driven by impaired Aβ clearance, creating conditions for a self-reinforcing cycle of increased vascular Aβ, reduced perivascular clearance and further CAA and AD progression. Despite the close relationship between vascular and plaque Aβ deposition, several factors favour one or the other, such as the carboxy-terminal site of the peptide and specific co-deposited proteins. Amyloid-related imaging abnormalities that have been seen in trials of anti-Aβ immunotherapy are another probable intersection between CAA and AD, representing overload of perivascular clearance pathways and the effects of removing Aβ from CAA-positive vessels. The intersections between CAA and AD point to a crucial role for improving vascular function in the treatment of both diseases and indicate the next steps necessary for identifying therapies.
Amyloid-β (Aβ) in the brain interstitial fluid can be cleared via perivascular drainage pathways or deposited as neuritic plaques in the brain parenchyma or as cerebral amyloid angiopathy (CAA) along vessel walls.
Vascular dysfunction caused by CAA reduces perivascular Aβ clearance in animal models, creating a vicious cycle of vascular and parenchymal Aβ accumulation.
Factors that favour vascular Aβ deposition over parenchymal deposition include termination of Aβ at or before position 41, missense mutations within the Aβ coding region, and some co-deposited proteins, such as fibrinogen.
Amyloid-related imaging abnormalities observed in trials of anti-Aβ immunotherapy might result from mobilization of plaque Aβ into the perivascular drainage system or from antibody targeting of vascular Aβ deposits.
Development of methods for imaging perivascular drainage in humans would be a key step towards identifying treatments for enhancing Aβ clearance and reducing vascular and parenchymal deposition.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Corriveau, R. A. et al. The science of vascular contributions to cognitive impairment and dementia (VCID): a framework for advancing research priorities in the cerebrovascular biology of cognitive decline. Cell Mol. Neurobiol. 36, 281–288 (2016).
Boyle, P. A. et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann. Neurol. 83, 74–83 (2018).
Satizabal, C. L. et al. Incidence of dementia over three decades in the Framingham Heart Study. N. Engl. J. Med. 374, 523–532 (2016).
Iadecola, C. & Gottesman, R. F. Cerebrovascular alterations in Alzheimer disease. Circ. Res. 123, 406–408 (2018).
Tarasoff-Conway, J. M. et al. Clearance systems in the brain–implications for Alzheimer disease. Nat. Rev. Neurol. 11, 457–470 (2015).
Arvanitakis, Z. et al. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann. Neurol. 69, 320–327 (2011).
Brenowitz, W. D., Nelson, P. T., Besser, L. M., Heller, K. B. & Kukull, W. A. Cerebral amyloid angiopathy and its co-occurrence with Alzheimer’s disease and other cerebrovascular neuropathologic changes. Neurobiol. Ageing 36, 2702–2708 (2015).
Greenberg, S. M. & Charidimou, A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston criteria. Stroke 49, 491–497 (2018).
Yates, P. A. et al. Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology 82, 1266–1273 (2014).
De Strooper, B. & Karran, E. The cellular phase of Alzheimer’s disease. Cell 164, 603–615 (2016).
Guillozet, A. L., Weintraub, S., Mash, D. C. & Mesulam, M. M. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neurol. 60, 729–736 (2003).
Andrade-Moraes, C. H. et al. Cell number changes in Alzheimer’s disease relate to dementia, not to plaques and tangles. Brain 136, 3738–3752 (2013).
Villemagne, V. L. & Okamura, N. Tau imaging in the study of ageing, Alzheimer’s disease, and other neurodegenerative conditions. Curr. Opin. Neurobiol. 36, 43–51 (2016).
Villeneuve, S. et al. Cortical thickness mediates the effect of beta-amyloid on episodic memory. Neurology 82, 761–767 (2014).
Sperling, R. A. et al. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann. Neurol. 85, 181–193 (2019).
Greenberg, S. M. et al. Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurol. 13, 419–428 (2014).
Reijmer, Y. D. et al. Structural network alterations and neurological dysfunction in cerebral amyloid angiopathy. Brain 138, 179–188 (2015).
Dichgans, M. & Leys, D. Vascular cognitive impairment. Circ. Res. 120, 573–591 (2017).
van Veluw, S. J. et al. Histopathology of diffusion imaging abnormalities in cerebral amyloid angiopathy. Neurology 92, e933–e943 (2019).
van Veluw, S. J. et al. Detection, risk factors, and functional consequences of cerebral microinfarcts. Lancet Neurol. 16, 730–740 (2017).
Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W. & Greenberg, S. M. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann. Neurol. 55, 250–256 (2004).
van Veluw, S. J. et al. Different microvascular alterations underlie microbleeds and microinfarcts. Ann. Neurol. 86, 279–292 (2019).
Dumas, A. et al. Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy. Ann. Neurol. 72, 76–81 (2012).
Peca, S. et al. Neurovascular decoupling is associated with severity of cerebral amyloid angiopathy. Neurology 81, 1659–1665 (2013).
van Opstal, A. M. et al. Cerebrovascular function in presymptomatic and symptomatic individuals with hereditary cerebral amyloid angiopathy: a case-control study. Lancet Neurol. 16, 115–122 (2017). This study, along with Dumas et al. and Peca et al., demonstrated impairment of vascular reactivity to physiological stimulation in CAA, a mechanism that may contribute to tissue injury and delayed perivascular clearance.
Iturria-Medina, Y. et al. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat. Commun. 7, 11934 (2016).
Grabowski, T. J., Cho, H. S., Vonsattel, J. P., Rebeck, G. W. & Greenberg, S. M. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol. 49, 697–705 (2001).
Fotiadis, P. et al. Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study. Lancet Neurol. 15, 811–819 (2016).
Goos, J. D. et al. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke 40, 3455–3460 (2009).
Boyle, P. A. et al. Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology 85, 1930–1936 (2015).
Szentistvanyi, I., Patlak, C. S., Ellis, R. A. & Cserr, H. F. Drainage of interstitial fluid from different regions of rat brain. Am. J. Physiol. 246, F835–F844 (1984).
Zhang, E. T., Richards, H. K., Kida, S. & Weller, R. O. Directional and compartmentalised drainage of interstitial fluid and cerebrospinal fluid from the rat brain. Acta Neuropathol. 83, 233–239 (1992).
Kida, S., Pantazis, A. & Weller, R. O. CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol. Appl. Neurobiol. 19, 480–488 (1993).
Weller, R. O. et al. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer’s disease. Am. J. Pathol. 153, 725–733 (1998). This study was an early statement of the experimental support for a link between CAA and the perivascular fluid drainage process.
Weller, R. O., Subash, M., Preston, S. D., Mazanti, I. & Carare, R. O. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol. 18, 253–266 (2008).
Carare, R. O., Hawkes, C. A., Jeffrey, M., Kalaria, R. N. & Weller, R. O. Review: cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. Neuropathol. Appl. Neurobiol. 39, 593–611 (2013).
Carare, R. O. et al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol. Appl. Neurobiol. 34, 131–144 (2008).
Albargothy, N. J. et al. Convective influx/glymphatic system: tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways. Acta Neuropathol. 136, 139–152 (2018).
Keable, A. et al. Deposition of amyloid beta in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathy. Biochim. Biophys. Acta 1862, 1037–1046 (2016).
Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci. Transl Med. 4, 147ra111 (2012).
Plog, B. A. & Nedergaard, M. The glymphatic system in central nervous system health and disease: past, present, and future. Annu. Rev. Pathol. 13, 379–394 (2018).
Benveniste, H. et al. The glymphatic system and waste clearance with brain aging: a review. Gerontology 65, 106–119 (2019).
Nedergaard, M. Neuroscience. Garbage truck of the brain. Science 340, 1529–1530 (2013).
Smith, A. J., Yao, X., Dix, J. A., Jin, B. J. & Verkman, A. S. Test of the ‘glymphatic’ hypothesis demonstrates diffusive and aquaporin-4-independent solute transport in rodent brain parenchyma. eLife 6, e27679 (2017).
Mestre, H. et al. Aquaporin-4-dependent glymphatic solute transport in the rodent brain. eLife 7, e40070 (2018).
Wilcock, D. M., Vitek, M. P. & Colton, C. A. Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer’s disease. Neuroscience 159, 1055–1069 (2009).
Bakker, E. N. et al. Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases. Cell Mol. Neurobiol. 36, 181–194 (2016).
Smith, A. J. & Verkman, A. S. The “glymphatic” mechanism for solute clearance in Alzheimer’s disease: game changer or unproven speculation? FASEB J. 32, 543–551 (2018).
Mestre, H. et al. Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nat. Commun. 9, 4878 (2018).
Schley, D., Carare-Nnadi, R., Please, C. P., Perry, V. H. & Weller, R. O. Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J. Theor. Biol. 238, 962–974 (2006).
Weller, R. O., Djuanda, E., Yow, H. Y. & Carare, R. O. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol. 117, 1–14 (2009).
Bedussi, B., Almasian, M., de Vos, J., VanBavel, E. & Bakker, E. N. Paravascular spaces at the brain surface: low resistance pathways for cerebrospinal fluid flow. J. Cereb. Blood Flow Metab. 38, 719–726 (2018).
Diem, A. K. et al. Arterial pulsations cannot drive intramural periarterial drainage: significance for Aβ drainage. Front. Neurosci. 11, 475 (2017).
Aldea, R., Weller, R. O., Wilcock, D. M., Carare, R. O. & Richardson, G. Cerebrovascular smooth muscle cells as the drivers of intramural periarterial drainage of the brain. Front. Ageing Neurosci. 11, 1 (2019).
Mateo, C., Knutsen, P. M., Tsai, P. S., Shih, A. Y. & Kleinfeld, D. Entrainment of arteriole vasomotor fluctuations by neural activity is a basis of blood-oxygenation-level-dependent “resting-state” connectivity. Neuron 96, 936–948 (2017). This study identified a link between resting neuronal activity and vasomotion, the proposed motor force for perivascular clearance.
He, Y. et al. Ultra-slow single-vessel BOLD and CBV-based fMRI spatiotemporal dynamics and their correlation with neuronal intracellular calcium signals. Neuron 97, 925–939 (2018).
van Veluw, S. J. et al. Vasomotion as a driving force for paravascular clearance in the awake mouse brain. Neuron https://doi.org/10.1016/j.neuron.2019.10.033 (2019).
Geurts, L. J., Zwanenburg, J. J. M., Klijn, C. J. M., Luijten, P. R. & Biessels, G. J. Higher pulsatility in cerebral perforating arteries in patients with small vessel disease related stroke, a 7T MRI study. Stroke 50, 62–68 (2019).
Eide, P. K. & Ringstad, G. MRI with intrathecal MRI gadolinium contrast medium administration: a possible method to assess glymphatic function in human brain. Acta Radiol. Open 4, 2058460115609635 (2015).
Ringstad, G., Vatnehol, S. A. S. & Eide, P. K. Glymphatic MRI in idiopathic normal pressure hydrocephalus. Brain 140, 2691–2705 (2017).
Arbel-Ornath, M. et al. Interstitial fluid drainage is impaired in ischemic stroke and Alzheimer’s disease mouse models. Acta Neuropathol. 126, 353–364 (2013).
Xu, Z. et al. Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits. Mol. Neurodegener. 10, 58 (2015).
Wardlaw, J. M., Smith, C. & Dichgans, M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 12, 483–497 (2013).
Charidimou, A. et al. MRI-visible perivascular spaces in cerebral amyloid angiopathy and hypertensive arteriopathy. Neurology 88, 1157–1164 (2017).
van Veluw, S. J. et al. Cerebral amyloid angiopathy severity is linked to dilation of juxtacortical perivascular spaces. J. Cereb. Blood Flow Metab. 36, 576–580 (2016).
Bouvy, W. H. et al. Microbleeds colocalize with enlarged juxtacortical perivascular spaces in amnestic mild cognitive impairment and early Alzheimer’s disease: a 7 Tesla MRI study. J. Cereb. Blood Flow Metab. https://doi.org/10.1177/0271678X19838087 (2019).
Garcia-Alloza, M. et al. Cerebrovascular lesions induce transient beta-amyloid deposition. Brain 134, 3697–3707 (2011).
Wang, M. et al. Focal solute trapping and global glymphatic pathway impairment in a murine model of multiple microinfarcts. J. Neurosci. 37, 2870–2877 (2017).
Weller, R. O., Yow, H. Y., Preston, S. D., Mazanti, I. & Nicoll, J. A. Cerebrovascular disease is a major factor in the failure of elimination of Abeta from the aging human brain: implications for therapy of Alzheimer’s disease. Ann. N. Y. Acad. Sci. 977, 162–168 (2002).
Hawkes, C. A. et al. Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-beta from the mouse brain. Aging. Cell 12, 224–236 (2013).
Kress, B. T. et al. Impairment of paravascular clearance pathways in the aging brain. Ann. Neurol. 76, 845–861 (2014).
Xie, L. et al. Sleep drives metabolite clearance from the adult brain. Science 342, 373–377 (2013).
Holth, J. K. et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science 363, 880–884 (2019).
Kang, J. E. et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005–1007 (2009).
Shokri-Kojori, E. et al. beta-Amyloid accumulation in the human brain after one night of sleep deprivation. Proc. Natl Acad. Sci. USA 115, 4483–4488 (2018).
Thal, D. R., Rub, U., Orantes, M. & Braak, H. Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791–1800 (2002).
Thal, D. R., Ghebremedhin, E., Orantes, M. & Wiestler, O. D. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J. Neuropathol. Exp. Neurol. 62, 1287–1301 (2003).
Thal, D. R. et al. Two types of sporadic cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 61, 282–293 (2002).
Makela, M., Paetau, A., Polvikoski, T., Myllykangas, L. & Tanskanen, M. Capillary amyloid-beta protein deposition in a population-based study (Vantaa 85+). J. Alzheimers Dis. 49, 149–157 (2016).
Attems, J. & Jellinger, K. A. Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology–a pilot study. Acta Neuropathol. 107, 83–90 (2004).
Vonsattel, J. P. et al. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann. Neurol. 30, 637–649 (1991).
Robbins, E. M. et al. Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. J. Neurosci. 26, 365–371 (2006).
Meyer-Luehmann, M. et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313, 1781–1784 (2006).
Jaunmuktane, Z. et al. Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature 525, 247–250 (2015). This initial report of human tissue transmitting early-onset CAA provides strong evidence for amyloid seeding as a mechanism of disease initiation.
Banerjee, G. et al. Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura. Ann. Neurol. 85, 284–290 (2019).
Miller, D. L. et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer’s disease. Arch. Biochem. Biophys. 301, 41–52 (1993).
Gravina, S. A. et al. Amyloid beta protein (A beta) in Alzheimer’s disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem. 270, 7013–7016 (1995).
Kakuda, N. et al. Distinct deposition of amyloid-β species in brains with Alzheimer’s disease pathology visualized with MALDI imaging mass spectrometry. Acta Neuropathol. Commun. 5, 73 (2017).
Roher, A. E. et al. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 10836–10840 (1993).
Attems, J., Lintner, F. & Jellinger, K. A. Amyloid beta peptide 1-42 highly correlates with ocapillary cerebral amyloid angiopathy and Alzheimer disease pathology. Acta Neuropathol. 107, 283–291 (2004).
Wisniewski, H. M. & Wegiel, J. Beta-amyloid formation by myocytes of leptomeningeal vessels. Acta Neuropathol. 87, 233–241 (1994).
Frackowiak, J., Miller, D. L., Potempska, A., Sukontasup, T. & Mazur-Kolecka, B. Secretion and accumulation of Abeta by brain vascular smooth muscle cells from AbetaPP-Swedish transgenic mice. J. Neuropathol. Exp. Neurol. 62, 685–696 (2003).
Calhoun, M. E. et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl Acad. Sci. USA 96, 14088–14093 (1999). This demonstration of CAA pathology in transgenic mice with neuronal expression of mutant amyloid precursor protein helped to establish the principle that neuronally derived amyloid-β can reach sites of deposition in vessel walls.
Herzig, M. C. et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 7, 954–960 (2004).
Jarrett, J. T., Berger, E. P. & Lansbury, P. T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32, 4693–4697 (1993).
McGowan, E. et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47, 191–199 (2005).
Harigaya, Y. et al. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer’s disease brain. Biochem. Biophys. Res. Commun. 276, 422–427 (2000).
Revesz, T. et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J. Neuropathol. Exp. Neurol. 62, 885–898 (2003).
Wattendorff, A. R., Frangione, B., Luyendijk, W. & Bots, G. T. Hereditary cerebral haemorrhage with amyloidosis, Dutch type (HCHWA-D): clinicopathological studies. J. Neurol. Neurosurg. Psychiatry 58, 699–705 (1995).
Levy, E. et al. Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124–1126 (1990).
Maat-Schieman, M. L., van Duinen, S. G., Bornebroek, M., Haan, J. & Roos, R. A. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): II–A review of histopathological aspects. Brain Pathol. 6, 115–120 (1996).
Kamino, K. et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am. J. Hum. Genet. 51, 998–1014 (1992).
Bugiani, O. et al. Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. Arch. Neurol. 67, 987–995 (2010).
Cras, P. et al. Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala–>Gly mutation. Acta Neuropathol. 96, 253–260 (1998).
Obici, L. et al. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann. Neurol. 58, 639–644 (2005).
Basun, H. et al. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch. Neurol. 65, 499–505 (2008).
Kumar-Singh, S. et al. Dense-core senile plaques in the Flemish variant of Alzheimer’s disease are vasocentric. Am. J. Pathol. 161, 507–520 (2002).
Mann, D. M. et al. Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer’s disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am. J. Pathol. 148, 1257–1266 (1996).
Shin, Y. et al. Abeta species, including IsoAsp23 Abeta, in Iowa-type familial cerebral amyloid angiopathy. Acta Neuropathol. 105, 252–258 (2003).
Greenberg, S. M. et al. Hemorrhagic stroke associated with the Iowa amyloid precursor protein mutation. Neurology 60, 1020–1022 (2003).
Brooks, W. S. et al. Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation. Neurology 63, 1613–1617 (2004).
Clements, A., Walsh, D. M., Williams, C. H. & Allsop, D. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer’s amyloid beta/A4 peptide. Neurosci. Lett. 161, 17–20 (1993).
Melchor, J. P., McVoy, L. & Van Nostrand, W. E. Charge alterations of E22 enhance the pathogenic properties of the amyloid beta-protein. J. Neurochem. 74, 2209–2212 (2000).
Van Nostrand, W. E., Melchor, J. P., Romanov, G., Zeigler, K. & Davis, J. Pathogenic effects of cerebral amyloid angiopathy mutations in the amyloid beta-protein precursor. Ann. N. Y. Acad. Sci. 977, 258–265 (2002).
Nilsberth, C. et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4, 887–893 (2001).
Fossati, S. et al. Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-beta variants in cells composing the cerebral vessel walls. FASEB J. 24, 229–241 (2010).
Miravalle, L. et al. Substitutions at codon 22 of Alzheimer’s abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J. Biol. Chem. 275, 27110–27116 (2000).
Tsubuki, S., Takaki, Y. & Saido, T. C. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 361, 1957–1958 (2003).
Morelli, L. et al. Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J. Biol. Chem. 278, 23221–23226 (2003).
Monro, O. R. et al. Substitution at codon 22 reduces clearance of Alzheimer’s amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol. Ageing. 23, 405–412 (2002).
Sleegers, K. et al. APP duplication is sufficient to cause early onset Alzheimer’s dementia with cerebral amyloid angiopathy. Brain 129, 2977–2983 (2006).
Rovelet-Lecrux, A. et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 24–26 (2006).
Wilcock, D. M., Schmitt, F. A. & Head, E. Cerebrovascular contributions to aging and Alzheimer’s disease in Down syndrome. Biochim. Biophys. Acta 1862, 909–914 (2016).
Nochlin, D., Bird, T. D., Nemens, E. J., Ball, M. J. & Sumi, S. M. Amyloid angiopathy in a Volga German family with Alzheimer’s disease and a presenilin-2 mutation (N141I). Ann. Neurol. 43, 131–135 (1998).
Dermaut, B. et al. Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer’s disease due to a novel presenilin 1 mutation. Brain 124, 2383–2392 (2001).
Sanchez-Valle, R. et al. A novel mutation in the PSEN1 gene (L286P) associated with familial early-onset dementia of Alzheimer type and lobar haematomas. Eur. J. Neurol. 14, 1409–1412 (2007).
Mann, D. M., Pickering-Brown, S. M., Takeuchi, A. & Iwatsubo, T. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer’s disease. Am. J. Pathol. 158, 2165–2175 (2001).
Ryan, N. S. et al. Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer’s disease. Neurobiol. Ageing. 36, 3140–3151 (2015).
Woo, D. et al. Meta-analysis of genome-wide association studies identifies 1q22 as a susceptibility locus for intracerebral hemorrhage. Am. J. Hum. Genet. 94, 511–521 (2014).
Marini, S. et al. Association of apolipoprotein E with intracerebral hemorrhage risk by race/ethnicity: a meta-analysis. JAMA Neurol. 76, 480–491 (2019).
Beecham, G. W. et al. Genome-wide association meta-analysis of neuropathologic features of Alzheimer’s disease and related dementias. PLOS Genet. 10, e1004606 (2014).
Makela, M. et al. Alzheimer risk loci and associated neuropathology in a population-based study (Vantaa 85+). Neurol. Genet. 4, e211 (2018). In this study and Beecham et al., associations between CAA pathology and genetic variants that promote Alzheimer disease pathology were examined.
Eikelenboom, P. & Stam, F. C. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. 57, 239–242 (1982).
Snow, A. D. et al. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer’s disease. Am. J. Pathol. 133, 456–463 (1988).
Kalaria, R. N. & Grahovac, I. Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: implications for leakage across the blood–brain barrier in Alzheimer’s disease. Brain Res. 516, 349–353 (1990).
Rozemuller, J. M. et al. Distribution pattern and functional state of α1-antichymotrypsin in plaques and vascular amyloid in Alzheimer’s disease. An immunohistochemical study with monoclonal antibodies against native and inactivated α1-antichymotrypsin. Acta Neuropathol. 82, 200–207 (1991).
Van Gool, D., De Strooper, B., Van Leuven, F., Triau, E. & Dom, R. α2-macroglobulin expression in neuritic-type plaques in patients with Alzheimer’s disease. Neurobiol. Ageing. 14, 233–237 (1993).
Verbeek, M. M. et al. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer’s disease. Am. J. Pathol. 144, 104–116 (1994).
McGeer, P. L., Klegeris, A., Walker, D. G., Yasuhara, O. & McGeer, E. G. Pathological proteins in senile plaques. Tohoku J. Exp. Med. 174, 269–277 (1994).
Harr, S. D., Uint, L., Hollister, R., Hyman, B. T. & Mendez, A. J. Brain expression of apolipoproteins E, J, and A-I in Alzheimer’s disease. J. Neurochem. 66, 2429–2435 (1996).
Verbeek, M. M., Otte-Holler, I., Veerhuis, R., Ruiter, D. J. & De Waal, R. M. Distribution of Aβ-associated proteins in cerebrovascular amyloid of Alzheimer’s disease. Acta Neuropathol. 96, 628–636 (1998).
Hashimoto, T. et al. CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO J. 21, 1524–1534 (2002).
Kowa, H. et al. Mostly separate distributions of CLAC- versus Abeta40- or thioflavin S-reactivities in senile plaques reveal two distinct subpopulations of beta-amyloid deposits. Am. J. Pathol. 165, 273–281 (2004).
Zabel, M. et al. A shift in microglial β-amyloid binding in Alzheimer’s disease is associated with cerebral amyloid angiopathy. Brain Pathol. 23, 390–401 (2013).
Camacho, J. et al. Brain ApoA-I, ApoJ and ApoE immunodetection in cerebral amyloid angiopathy. Front. Neurol 10, 187 (2019).
Ghiso, J. et al. The cerebrospinal-fluid soluble form of Alzheimer’s amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 293, 27–30 (1993).
Webster, S., O’Barr, S. & Rogers, J. Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q. J. Neurosci. Res. 39, 448–456 (1994).
Snow, A. D. et al. An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar aβ-amyloid in rat brain. Neuron 12, 219–234 (1994).
Ma, J., Yee, A., Brewer, H. B. J., Das, S. & Potter, H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372, 92–94 (1994).
Endo, Y. et al. Apolipoprotein E and clusterin inhibit the early phase of amyloid-beta aggregation in an in vitro model of cerebral amyloid angiopathy. Acta Neuropathol. Commun. 7, 12 (2019).
Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E. & Ikeda, K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541, 163–166 (1991).
Wisniewski, T., Golabek, A. A., Kida, E., Wisniewski, K. E. & Frangione, B. Conformational mimicry in Alzheimer’s disease. Role of apolipoproteins in amyloidogenesis. Am. J. Pathol. 147, 238–244 (1995).
Strittmatter, W. J. et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 1977–1981 (1993).
Liu, Y. et al. APOE genotype and neuroimaging markers of Alzheimer’s disease: systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 86, 127–134 (2015).
Greenberg, S. M., Rebeck, G. W., Vonsattel, J. P. V., Gomez-Isla, T. & Hyman, B. T. Apolipoprotein E e4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 38, 254–259 (1995).
Nicoll, J. A. & McCarron, M. O. APOE gene polymorphism as a risk factor for cerebral amyloid angiopathy-related hemorrhage. Amyloid 8, 51–55 (2001).
Olichney, J. M. et al. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer’s disease and Lewy body variant. Neurology 47, 190–196 (1996).
Corder, E. H. et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7, 180–184 (1994).
Deane, R. et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118, 4002–4013 (2008).
Verghese, P. B. et al. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc. Natl Acad. Sci. USA 110, E1807–E1816 (2013).
Huynh, T. V., Davis, A. A., Ulrich, J. D. & Holtzman, D. M. Apolipoprotein E and Alzheimer’s disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins. J. Lipid. Res. 58, 824–836 (2017).
Guo, S. et al. Effects of apoE isoforms on beta-amyloid-induced matrix metalloproteinase-9 in rat astrocytes. Brain Res. 1111, 222–226 (2006).
Bales, K. R. et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17, 263–264 (1997).
Fryer, J. D. et al. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J. Neurosci. 23, 7889–7896 (2003).
Holtzman, D. M. et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA 97, 2892–2897 (2000).
Holtzman, D. M. et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer’s disease. J. Clin. Invest. 103, 15–21 (1999).
Fryer, J. D. et al. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25, 2803–2810 (2005). This study, Fryer et al. (2003), Holtzman et al. (2000) and Holtzman et al. (1999) demonstrate the complex relationship between CAA pathology and the presence of apolipoprotein E, its isoforms, and its human and mouse forms.
Liao, F. et al. Murine versus human apolipoprotein E4: differential facilitation of and colocalization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathol. Commun. 3, 70 (2015).
Thal, D. R. et al. Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer’s disease. Acta Neuropathol. 120, 169–183 (2010).
McGeer, P. L., Kawamata, T. & Walker, D. G. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 579, 337–341 (1992).
Miners, J. S., Clarke, P. & Love, S. Clusterin levels are increased in Alzheimer’s disease and influence the regional distribution of Aβ. Brain Pathol. 27, 305–313 (2017).
Hammad, S. M., Ranganathan, S., Loukinova, E., Twal, W. O. & Argraves, W. S. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. J. Biol. Chem. 272, 18644–18649 (1997).
Narayan, P. et al. The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-beta(1-40) peptide. Nat. Struct. Mol. Biol. 19, 79–83 (2011).
Yerbury, J. J. et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 21, 2312–2322 (2007).
Wojtas, A. M. et al. Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. Proc. Natl Acad. Sci. USA 114, E6962–E6971 (2017).
Bell, R. D. et al. Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood. Flow Metab. 27, 909–918 (2007).
DeMattos, R. B. et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA 99, 10843–10848 (2002).
Oh, S. B. et al. Clusterin contributes to early stage of Alzheimer’s disease pathogenesis. Brain Pathol. 29, 217–231 (2019).
Drummond, E. et al. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease. Acta Neuropathol. 133, 933–954 (2017).
Xiong, F., Ge, W. & Ma, C. Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer’s disease. Alzheimers Dement. 15, 429–440 (2019).
Manousopoulou, A. et al. Systems proteomic analysis reveals that clusterin and tissue inhibitor of metalloproteinases 3 increase in leptomeningeal arteries affected by cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol. 43, 492–504 (2017).
Hondius, D. C. et al. Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer’s disease. Acta Neuropathol. Commun. 6, 46 (2018).
Inoue, Y. et al. Sushi repeat-containing protein 1: a novel disease-associated molecule in cerebral amyloid angiopathy. Acta Neuropathol. 134, 605–617 (2017).
Cortes-Canteli, M. et al. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer’s disease. Neuron 66, 695–709 (2010).
Hultman, K., Strickland, S. & Norris, E. H. The APOE ε4/ε4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer’s disease patients. J. Cereb. Blood Flow Metab. 33, 1251–1258 (2013).
Sperling, R. A. et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367–385 (2011).
Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. New Engl. J. Med. 370, 322–333 (2014).
Ostrowitzki, S. et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res. Ther. 9, 95 (2017).
Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).
Carlson, C. et al. Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer’s disease. Alzheimers Dement. (Amst) 2, 75–85 (2016).
Cummings, J. L. et al. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology 90, e1889–e1897 (2018).
Leurent, C. et al. Immunotherapy with ponezumab for probable cerebral amyloid angiopathy. Ann. Clin. Transl Neurol. 6, 795–806 (2019). The initial clinical trial of anti-amyloid-β immunotherapy in patients diagnosed with CAA cerebral amyloid angiopathy.
Ultsch, M. et al. Structure of crenezumab complex with Aβ shows loss of β-hairpin. Sci. Rep. 6, 39374 (2016).
Raman, M. R. et al. Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult. Neurology 83, 1771–1772 (2014).
Ryan, N. S. et al. Spontaneous ARIA (amyloid-related imaging abnormalities) and cerebral amyloid angiopathy related inflammation in presenilin 1-associated familial Alzheimer’s disease. J. Alzheimers Dis. 44, 1069–1074 (2015).
Ketter, N. et al. Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer’s disease patients. J. Alzheimers Dis. 57, 557–573 (2017).
Penninkilampi, R., Brothers, H. M. & Eslick, G. D. Safety and efficacy of anti-amyloid-β immunotherapy in Alzheimer’s disease: a systematic review and meta-analysis. J. Neuroimmune Pharmacol. 12, 194–203 (2017).
Goos, J. D. et al. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology 74, 1954–1960 (2010).
Haeberlein, S. B. et al. 24-Month analysis of change from baseline in clinical dementia rating scale cognitive and functional domains in PRIME: a randomized phase 1b study of the anti-amyloid beta monoclonal antibody aducanumab [abstract O1-09-06]. Alzheimers Dement. 14 (Suppl. 7), P242 (2018).
Andjelkovic, M. et al. Update on the safety and tolerability of gangenerumab in the ongoing open-label extension of the SCarlet RoAD study in patients with prodromal Alzheimer’s disease after approximately 2 years of study duration [abstract O1-09-05]. Alzheimers Dement. 14 (Suppl. 7), P241–P242 (2018).
Sperling, R. et al. Amyloid-related imaging abnormalities in patients with Alzheimer disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11, 241–249 (2012). An analysis of amyloid-related imaging abnormalities in clinical trials of the anti-amyloid-β antibody bapineuzumab and in which candidate mechanisms were proposed.
Arrighi, H. M. et al. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer’s disease treated with bapineuzumab: a historical, prospective secondary analysis. J. Neurol. Neurosurg. Psychiatry. 87, 106–112 (2016).
Brashear, H. R. et al. Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab phase III studies. J Alzheimers Dis. 66, 1409–1424 (2018).
Liu, E. et al. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology 90, e877–e886 (2018).
Boche, D., Denham, N., Holmes, C. & Nicoll, J. A. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer’s disease pathogenesis. Acta Neuropathol. 120, 369–384 (2010).
Sakai, K. et al. Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy. Acta Neuropathol. 128, 777–789 (2014).
Mandybur, T. I. Cerebral amyloid angiopathy: the vascular pathology and complications. J. Neuropathol. Exp. Neurol. 45, 79–90 (1986).
Kinnecom, C. et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 68, 1411–1416 (2007).
Auriel, E. et al. Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol. 73, 197–202 (2016).
Piazza, F. et al. Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann. Neurol. 73, 449–458 (2013). The first report of anti-amyloid-β antibodies in the CSF of individuals with CAA, offering the strongest link between this spontaneous syndrome and ARIA seen in clinical trials of anti-amyloid-β antibodies.
Zago, W. et al. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: implications for amyloid-related imaging abnormalities. Alzheimers Dement. 9, S105-S115 (2013).
Blockx, I. et al. Monitoring blood–brain barrier integrity following amyloid-β immunotherapy using gadolinium-enhanced MRI in a PDAPP mouse model. J. Alzheimers Dis. 54, 723–735 (2016).
Gottesman, R. F. et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 74, 1246–1254 (2017).
Boche, D. et al. Consequence of Abeta immunization on the vasculature of human Alzheimer’s disease brain. Brain 131, 3299–3310 (2008). This study identified changes in CAA severity in post-mortem brain tissue from individiuals who were previously immunized against amyloid-β.
Han, B. H. et al. Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy. Mol. Neurodegener. 6, 86 (2011).
Mawuenyega, K. G. et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330, 1774 (2010).
de Leon, M. J. et al. Cerebrospinal fluid clearance in Alzheimer disease measured with dynamic PET. J. Nucl. Med. 58, 1471–1476 (2017).
Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349, 704–706 (1991).
Mullan, M. et al. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1, 345–347 (1992).
Rovelet-Lecrux, A. et al. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J. Neurol. Neurosurg. Psychiatry. 78, 1158–1159 (2007).
Belza, M. G. & Urich, H. Cerebral amyloid angiopathy in Down’s syndrome. Clin. neuropathology 5, 257–260 (1986).
Nicoll, J. A. et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann. Neurol. 41, 716–721 (1997).
Greenberg, S. M. et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 50, 961–965 (1998).
Cotman, S. L., Halfter, W. & Cole, G. J. Agrin binds to β-amyloid (Aβ), accelerates Aβ fibril formation, and is localized to Aβ deposits in Alzheimer’s disease brain. Mol. Cell Neurosci. 15, 183–198 (2000).
van Horssen, J. et al. Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer’s disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol. 102, 604–614 (2001).
Wilhelmus, M. M. et al. Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer’s disease brains. Neuropathol. Appl. Neurobiol. 32, 119–130 (2006).
Wilhelmus, M. M. et al. Small heat shock protein HspB8: its distribution in Alzheimer’s disease brains and its inhibition of amyloid-beta protein aggregation and cerebrovascular amyloid-beta toxicity. Acta Neuropathol. 111, 139–149 (2006).
van Horssen, J. et al. Collagen XVIII: a novel heparan sulfate proteoglycan associated with vascular amyloid depositions and senile plaques in Alzheimer’s disease brains. Brain Pathol. 12, 456–462 (2002).
Verbeek, M. M., Otte-Höller, I., Wesseling, P., Ruiter, D. J. & de Waal, R. M. Induction of alpha-smooth muscle actin expression in cultured human brain pericytes by transforming growth factor-beta 1. Am. J. Pathol. 144, 372–382 (1994).
Zhao, L. et al. Matrix metalloproteinase 9-mediated intracerebral hemorrhage induced by cerebral amyloid angiopathy. Neurobiol. Ageing 36, 2963–2971 (2015).
S.M.G. acknowledges research funding from the National Institutes of Health (R01 NS096730, R01 AG26484, U24 NS100591).
S.M.G. has served as a consultant or safety monitor for Alzheimer immunotherapy trials for Biogen, DIAN-TU and Roche. R.S. has served as a consultant or received clinical research funding from Biogen, Eisai, Eli Lilly, Janssen, Roche and Takeda. All other authors declare no competing interests.
Peer review information
Nature Reviews Neurology thanks J. Nicoll, M. Verbeek and M. Yamada for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Greenberg, S.M., Bacskai, B.J., Hernandez-Guillamon, M. et al. Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways. Nat Rev Neurol 16, 30–42 (2020). https://doi.org/10.1038/s41582-019-0281-2
Novel Blood-Derived Extracellular Vesicle-Based Biomarkers in Alzheimer’s Disease Identified by Proximity Extension Assay
Journal of Alzheimer's Disease (2020)
Nuclear Medicine and Biology (2020)
ACS Chemical Neuroscience (2020)
Non-linear Relationship Between Plasma Amyloid-β 40 Level and Cognitive Decline in a Cognitively Normal Population
Frontiers in Aging Neuroscience (2020)